For patients with symptomatic disease demanding therapy, ibrutinib is often advised depending on four phase III randomized clinical trials evaluating ibrutinib with chlorambucil monotherapy106 and various usually applied CIT combos, specifically FCR, bendamustine furthermore rituximab and chlorambucil in addition obinutuzumab (ClbO).107–109 Ibrut